연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
1401. Serum des-R prothrombin activation peptide fragment 2: a novel prognostic marker for disseminated intravascular coagulation.
Chung S, Kim JE, Kim HK, Yeon EH, Shin YS, Kim CW.
Thromb Res. 2013 Jun;131(6):547-53. doi: 10.1016/j.thromres.2013.04.015. Epub 2013 May 7.
Link
1400. Coagulation proteins influencing global coagulation assays in cirrhosis: hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay.
Youngwon N, Kim JE, Lim HS, Han KS, Kim HK.
Biomed Res Int. 2013;2013:856754. doi: 10.1155/2013/856754. Epub 2013 Feb 21.
Link
1399. Influence of coagulation and anticoagulant factors on global coagulation assays in healthy adults.
Kim SY, Kim JE, Kim HK, Kim I, Yoon SS, Park S.
Am J Clin Pathol. 2013 Mar;139(3):370-9. doi: 10.1309/AJCPC5C4AGFRDKMX.
Link
1398. Higher prognostic value of soluble fibrin complexes than D-dimer and fibrin degradation product for disseminated intravascular coagulation in patients with liver cirrhosis.
Kim SY, Kim JE, Kim HK, Kim I, Yoon SS, Park S.
Blood Coagul Fibrinolysis. 2013 Mar;24(2):150-6. doi: 10.1097/MBC.0b013e32835aef6b.
Link
1397. Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.
Lee YY1, Kim HP, Kang MJ, Cho BK, Han SW, Kim TY, Yi EC.
Exp Mol Med. 2013 Nov 22;45:e64. doi: 10.1038/emm.2013.115.
Link
1396. Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells.
Kang MJ1, Kim HP, Lee KS, Yoo YD, Kwon YT, Kim KM, Kim TY, Yi EC.
Proteomics. 2013 May;13(10-11):1714-25. doi: 10.1002/pmic.201200511. Epub 2013 Apr 23.
Link
1395. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.
Han SW1, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, Won JK, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Seo JS, Kim JI, Kim TY.
PLoS One. 2013 May 21;8(5):e64271. doi: 10.1371/journal.pone.0064271. Print 2013.
Link
1394. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW1, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.
Int J Cancer. 2013 May 1;132(9):2209-16. doi: 10.1002/ijc.27888. Epub 2012 Oct 29.
Link
1393. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.
Lee KH1, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, Kim SY, Lee KW, Kim JH, Hong YS, Kim TW, Park YS, Kang WK, Shin SJ, Ahn JB, Kang GH, Jeong SY, Park KJ, Park JG, Kim TY.
Cancer Chemother Pharmacol. 2013 Apr;71(4):843-51. doi: 10.1007/s00280-013-2075-3. Epub 2013 Jan 13.
Link
1392. The beneficial effect of palliative resection in metastatic colorectal cancer.
Park JH1, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kang GH, Chie EK, Ha SW, Jeong SY, Park KJ, Park JG, Kim TY.
Br J Cancer. 2013 Apr 16;108(7):1425-31. doi: 10.1038/bjc.2013.94. Epub 2013 Mar 12.
Link